Folate receptor in adenocarcinoma and squamous cell carcinoma of the lung: Potential target for folate-linked therapeutic agents

Archives of Pathology and Laboratory Medicine

Volumn 137, Issue 2, 2013, Pages 241-244

  Cagle, Philip T ^a   Zhai, Qihui Jim ^b,e   Murphy, Linda ^c   Low, Philip S ^d  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

^d PURDUE UNIVERSITY   (United States)

^e MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DERIVATIVE; FOLATE RECEPTOR 1; FOLIC ACID; FOLR1 PROTEIN, HUMAN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TISSUE MICROARRAY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLATE RECEPTOR 1; FOLIC ACID; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; TISSUE ARRAY ANALYSIS;

EID: 84874716108     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2012-0176-OA     Document Type: Article

References (46)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4): 212-236.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2): 69-90.
3. Youlden DR, Cramb SM, Baade PD. The international epidemiology of lung cancer: geographical distribution and secular trends. J Thorac Oncol. 2008;3(8): 819-831.
4. Cagle PT. Carcinoma of the lung. In: Churg AM, Myers JL, Tazelaar HD, Wright JL, eds. Pathology of the Lung. 3rd ed. New York, NY: Thieme Medical Publishers; 2005: 413-479.
5. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1): 10-29.
6. Cagle PT, Chirieac LR. Advances in treatment of lung cancer with targeted therapy. Arch Pathol Lab Med. 2012;136(5): 504-509.
7. Cagle PT, Allen TC, Dacic S, et al. Revolution in lung cancer: new challenges for the surgical pathologist. Arch Pathol Lab Med. 2011;135(1): 110-116.
8. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2): 244-285.
9. Cagle PT, Dacic S. Lung cancer and the future of pathology. Arch Pathol Lab Med. 2011;135(3): 293-295.
10. Dacic S. Molecular diagnostics of lung carcinomas. Arch Pathol Lab Med. 2011;135(5): 622-629.
11. Hirsch FR, Wynes MW, Gandara DR, Bunn PA Jr. The tissue is the issue: personalized medicine for non-small cell lung cancer. Clin Cancer Res. 2010; 16(20): 4909-4911.
12. Chirieac LR, Dacic S. Targeted therapies in lung cancer. Surg Pathol Clin. 2010;3(1): 71-82.
13. Sasaki T, Rodig SJ, Chirieac LR, Jänne PA. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer. 2010;46(10): 1773-1780.
14. Francis H, Solomon B. The current status of targeted therapy for non-small cell lung cancer. Intern Med J. 2010;40(9): 611-618.
15. Yoshida T, Zhang G, Haura EB. Targeting epidermal growth factor receptor: central signaling kinase in lung cancer. Biochem Pharmacol. 2010;80(5): 613-623.
16. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361(10): 947-957.
17. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18): 1693-1703.
18. Lindeman N, Cagle PT, Ladanyi M, et al. College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Lung Cancer biomarker guidelines. Arch Pathol Lab Med. In press.
19. Solomon B, Varella-Garcia M, Camidge DR. ALK gene rearrangements: a new therapeutic target inamolecularly defined subset of non-small cell lung cancer. J Thorac Oncol. 2009;4(12): 1450-1454.
20. Weickhardt AJ, Camidge DR. The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence. Clin Invest. 2011;1(8): 1119-1126.
21. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 2007;98(12): 1817-1824.
22. Suda K, Tomizawa K, Mitsudomi T. Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev. 2010;29(1): 49-60.
23. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011;12(11): 1004-1012.
24. Atherly AJ, Camidge DR. The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers [published online ahead of print February 28, 2012]. Br J Cancer. 2012;106(6): 1100-1106.
25. Rekhtman N, Paik PK, Arcila ME, et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res. 2012; 18(4): 1167-1176.
26. Matherly LH, Hou Z, Deng Y. Human reduced folate carrier: translation of basic biology to cancer etiology and therapy. Cancer Metastasis Rev. 2007;26(1): 111-128.
27. Zhao R, Goldman ID. Molecular identity and characterization of a Protoncoupled Folate Transporter-PCFT; biological ramifications and impact on the activity of pemetrexed. Cancer Metastasis Rev. 2007;26(1): 129-139.
28. Salazar MD, Ratnam M. The folate receptor: what does it promise in tissuetargeted therapeutics? Cancer Metastasis Rev. 2007;26(1): 141-152.
29. Kamen BA, Smith AK. A review of folate receptor alpha cycling and 5- methyltetrahydrofolate accumulation with an emphasis on cell models in vitro. Adv Drug Deliv Rev. 2004;56(8): 1085-1097.
30. Low PS, Henne WA, Doorneweerd DD. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem Res. 2008;41(1): 120-129.
31. Leamon CP. Folate-targeted drug strategies for the treatment of cancer. Curr Opin Investig Drugs. 2008;9(12): 1277-1286.
32. Hilgenbrink AR, Low PS. Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J Pharm Sci. 2005;94(10): 2135-2146.
33. Pan X, Lee RJ. Tumour-selective drug delivery via folate receptor-targeted liposomes. Expert Opin Drug Deliv. 2004;1(1): 7-17.
34. Kelemen LE. The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander? Int J Cancer. 2006;119(2): 243-250.
35. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP. Folate receptor expression in carcinomas and normal tissues determined byaquantitative radioligand binding assay. Anal Biochem. 2005;(2); 338: 284-293.
36. Toffoli G, Cernigoi C, Russo A, Gallo A, Bagnoli M, Boiocchi M. Overexpression of folate binding protein in ovarian cancers. Int J Cancer. 1997; 74(2): 193-198.
37. Hartmann LC, Keeney GL, Lingle WL, et al. Folate receptor overexpression is associated with poor outcome in breast cancer. Int J Cancer. 2007;121(5): 938-942.
38. Shia J, Klimstra DS, Nitzkorski JR, et al. Immunohistochemical expression of folate receptor alpha in colorectal carcinoma: patterns and biological significance. Hum Pathol. 2008;39(4): 498-505.
39. Iwakiri S, Sonobe M, Nagai S, Hirata T, Wada H, Miyahara R. Expression status of folate receptor alpha is significantly correlated with prognosis in nonsmall- cell lung cancers. Ann Surg Oncol. 2008;15(3): 889-899.
40. Franklin WA, Waintrub M, Edwards D, et al. New anti-lung-cancer antibody cluster 12 reacts with human folate receptors present on adenocarcinoma. Int J Cancer Suppl. 1994;8: 89-95.
41. Wang S, Luo J, Lantrip DA, et al. Design and synthesis of [111In]DTPAfolate for use asatumor-targeted radiopharmaceutical. Bioconjug Chem. 1997; 8(5): 673-679.
42. Sega EI, Low PS. Tumor detection using folate receptor-targeted imaging agents. Cancer Metastasis Rev. 2008;27(4): 655-664.
43. Lu Y, Sega E, Low PS. Folate receptor-targeted immunotherapy: induction of humoral and cellular immunity against hapten-decorated cancer cells. Int J Cancer. 2005;116(5): 710-719.
44. Reddy JA, Dorton R, Westrick E, et al. Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate. Cancer Res. 2007;67(9): 4434-4442.
45. Leamon CP, Reddy JA, Vlahov IR, et al. Preclinical antitumor activity ofanovel folate-targeted dual drug conjugate. Mol Pharm. 2007;4(5): 659-667.
46. Reddy JA, Xu LC, Parker N, Vetzel M, Leamon CP. Preclinical evaluation of (99m)Tc-EC20 for imaging folate receptor-positive tumors. J Nucl Med. 2004; 45(5): 857-866.